Final patient treated in PolyNovo BTM trial

Calzada (ASX:CZD) subsidiary PolyNovo announced the treatment of the final patient involved in its clinical trial of NovoSorb BTM in free-flap donor site repair.

PolyNovo now expects to report final efficiency results from the 10-patient trial in early October. Preliminary findings from the first nine patients have been encouraging, the company announced.

The procedures were conducted at Royal Adelaide Hospital, under the watch of principal investigator professor John Greenwood. The trial commenced in April 2012.

BTM, or Biodegradable Temporising Matrix, is a dermal scaffold treatment primarily designed for use in burns and other full-thickness wounds. PolyNovo said the plastic surgeons involved in the trial have expressed a desire to keep using NovoSorb BTM in their general patient population.

This might result in PolyNovo supplying the product to the hospital under the TGA’s special access scheme.

Greenwood has secured ethics committee approval for a separate trial of NovoSorb BTM in burn victims who have up to 50% body-surface burns. This trial is expected to commence recruitment in the fourth quarter.

PolyNovo this month formed a joint venture in the US to co-develop and market products based on its NovoSorb polymer technology for the facial-implant and plastic-surgery market.

Calzada shares were trading 1.43% lower at $0.069 as of around 2 pm on Monday.